Compare HubSpot Inc (HUBS) vs Pfizer Inc (PFE) Price & Performance

HubSpot (HUBS) trades at $215.91, up 2.64% today but remains in a bearish technical trend. The company reported strong Q2 2026 earnings with EPS of $3.26 beating estimates, but lowered customer growth guidance to 5,000-6,000 per quarter. Revenue grew 20% year-over-year to $3.13 billion in 2025, with net income improving to $45.91 million. However, the stock faces headwinds from AI transition costs and a securities fraud investigation announced on August 10, 2026.

Despite near-term challenges, HubSpot maintains strong fundamentals with 76.6% analyst buy ratings and a $233.93 consensus target. The AI pivot creates execution risk but offers long-term growth potential. Key risks include customer acquisition slowdown, competitive pressures, and legal uncertainties. Current valuation at 78.5x P/E requires sustained execution for further upside.

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.